IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday

IGM Biosciences (NASDAQ:IGMS - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $4.25 million for the quarter.

IGM Biosciences (NASDAQ:IGMS - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.13. IGM Biosciences had a negative net margin of 7,534.03% and a negative return on equity of 155.42%. The firm had revenue of $0.41 million during the quarter, compared to analysts' expectations of $0.39 million. On average, analysts expect IGM Biosciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

IGM Biosciences Stock Performance

Shares of IGMS stock traded up $0.01 during trading hours on Friday, hitting $1.14. The company had a trading volume of 225,006 shares, compared to its average volume of 328,395. IGM Biosciences has a 12 month low of $0.92 and a 12 month high of $22.50. The firm's fifty day moving average is $1.24 and its 200 day moving average is $4.75. The firm has a market capitalization of $68.14 million, a price-to-earnings ratio of -0.31 and a beta of 0.61.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. upgraded shares of IGM Biosciences from an "underweight" rating to a "neutral" rating in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the company's stock. Based on data from MarketBeat, IGM Biosciences has a consensus rating of "Hold" and a consensus price target of $5.50.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.